W
hen the fi rst issue of the Community Eye Health Journal was being sent to readers around the world in 1988, trachoma was at a turning point. One of the two foundational clinical trials establishing the eff ectiveness of the bilamellar tarsal rotation procedure for trachomatous trichiasis had just been completed; the other was about to start.
1,2
The pharmacokinetics and antimicrobial spectrum of azithromycin, a recently discovered macrolide antibiotic, were in the process of being defi ned. 3, 4 The epidemiological association between a lack of facial cleanliness and the presence of active trachoma was becoming clearly established 5, 6 and the World Health Organization's (WHO's) simplifi ed grading system had just been published, 7 providing non-specialist health personnel working in endemic communities with a means to clearly and quickly identify and record the burden of disease. Additionally, the fi rst national survey of the prevalence and causes of blindness in a country in Africa had just fi nished; it was conducted in The Gambia and suggested that 17% of all blindness there was due to trachoma.
8
These developments led, in the subsequent decade, to:
• Demonstration of the eff ectiveness of single-dose oral azithromycin against active trachoma, 9 successful trials of azithromycin mass drug administration, 10 and the initiation of a donation scheme by Pfi zer, Inc., the manufacturer of azithromycin • The 1998 World Health Assembly resolution 51.11, which called on endemic countries and WHO to take all actions necessary to achieve the GET2020 goal.
16

The current landscape
As a consequence of the above, the landscape for trachoma now looks very diff erent.The SAFE strategy is being implemented, partially or at scale, in at least 31 countries. In 2016, the year for which the most recent global data are available, more than 260,000 people had their trachomatous trichiasis managed, while more than 85 million people received antibiotics for trachoma.
17 Pfi zer's azithromycin (Zithromax ® ) donation scheme has ramped up from one hundred thousand doses shipped in 1999, to more than one hundred and twenty million doses shipped in 2016.
18 As a result, global antibiotic coverage is expected to increase again from 2016 to 2017.
17
Much of these recent increases in output of the SAFE strategy's surgery and antibiotic components rely on data from the Global Trachoma Mapping Project (GTMP), 19 which from 2012-2016 completed populationbased prevalence surveys in 1546 districts of 29 countries, adding to the 1,115 districts for which data had previously been amassed. 20 By working with health ministries to generate gold-standard data on trachoma prevalence within a culture of collaboration, openness and commitment to quality, 21,22 the GTMP helped foster a spirit of genuine collaboration within the trachoma elimination community, shone a light that has helped the rest of the world to see the ongoing public health tragedy of trachoma, and provided the district-bydistrict justifi cation required to initiate interventions. The Community Eye Health Journal has been a part of this journey. In its fi rst 100 issues, it has published more than 50 excellent articles about trachoma (www.cehjournal.org/category/trachoma/), providing a critical forum for education, information, debate and refl ection. We congratulate the Journal on its century, and thank the editors, donors and readers who have contributed so much to international eff orts against trachoma to date.
It would be wrong, however, to imply through these notes of congratulation that the race against trachoma has now been successfully run, or even that we could coast in from here to the fi nish line. Signifi cant challenges remain.
1 There is an urgent need to address the remaining gap between the resources that have been committed and those that will be required. 2 Important work is also needed on a number of technical issues, including:
a. How best to manage post-operative trachomatous trichiasis b. How to most effi ciently deliver water, hygiene and sanitation interventions to cut transmission of ocular Chlamydia trachomatis c. How to undertake post-validation surveillance of previously-endemic districts, in order to guard against recrudescence of infection and disease.
It is our hope that with the ongoing political support of endemic country governments, current programmatic momentum, the continuing commitment of our many partners, and the relevance of our work to a multitude of cross-cutting targets within the Sustainable Development Goals, 25 the end of trachoma can be achieved. 
